Administrative retreats: a new twist to avoid "administrative isolation".
Humans; Education; Schools; *Interpersonal Relations; *Administrative Personnel; Pharmacy/*organization & administration
Allen David D; Calhoun Larry D
American journal of pharmaceutical education
2006
2006-12
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.5688/aj7006147" target="_blank" rel="noreferrer noopener">10.5688/aj7006147</a>
Interdisciplinary Healthcare Education: Fact or Fiction?
Allen David D; Penn Mark A; Nora Lois Margaret
American journal of pharmaceutical education
2006
2006-05
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.5688/aj700239" target="_blank" rel="noreferrer noopener">10.5688/aj700239</a>
The blood-brain barrier choline transporter.
Humans; Animals; Drug Delivery Systems/*methods; Blood-Brain Barrier/drug effects/*metabolism; Membrane Transport Proteins/*metabolism; Organic Cation Transport Proteins/metabolism; Organic Cation Transporter 1/metabolism; Organic Cation Transporter 2
Drug delivery to the brain is made difficult by the blood-brain barrier (BBB) which is selectively permeable to organic drug compounds. Several membrane solute and nutrient transporters are expressed in the BBB vasculature, which may be utilized as mechanism of delivery of drugs to the brain. Of interest to us, are the organic cation transporters which could be used to transport cationic compounds into the CNS. In this mini-review, we will review the current understanding of the structural requirements for designing compounds which could effectively use organic cation transporters (OCT). For the first time, structural requirements for both OCT1 and OCT2 versus the BBB choline transporter (BBBCHT) are discussed and compared. The information gained here could increase the success rate in successful CNS drug delivery and therapeutics.
Geldenhuys Werner J; Allen David D
Central nervous system agents in medicinal chemistry
2012
2012-06
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.2174/187152412800792670" target="_blank" rel="noreferrer noopener">10.2174/187152412800792670</a>
Novel models for assessing blood-brain barrier drug permeation.
Humans; Animals; Blood-Brain Barrier/*metabolism; *Capillary Permeability; Drosophila melanogaster/metabolism; Grasshoppers/metabolism; High-Throughput Screening Assays; Pharmaceutical Preparations/*metabolism; Zebrafish/metabolism; Models; Animal
INTRODUCTION: The blood-brain barrier (BBB) is a selectively permeable micro-vascular unit which prevents many central nervous system (CNS)-targeted compounds from reaching the brain. A significant problem in CNS drug development is the ability to model BBB permeability in a timely, reproducible and cost-effective manner. Through the years, several models have been used such as artificial membranes, cell culture and animal models. AREAS COVERED: In this focused review, the authors cover novel models which have been developed or are in the process of being developed which can be used in modeling BBB. These models can either be used to determine BBB permeability or whether a compound may be disrupting the BBB. Many of these models lend themselves to high-throughput screening. The main model organisms covered here are the grasshopper (Locusta migratoria), fruit fly (Drosophila melanogaster) and zebrafish (Danio rerio). EXPERT OPINION: Many of the models covered here have only recently been utilized for BBB studies and still needs to be fully studied for its impact on reducing costs during drug development. The strength of these models lay in the fact that a whole organism experiment can be done in high throughput fashion as compared with classical vertebrate models such as micro-dialysis.
Geldenhuys Werner J; Allen David D; Bloomquist Jeffrey R
Expert opinion on drug metabolism & toxicology
2012
2012-06
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1517/17425255.2012.677433" target="_blank" rel="noreferrer noopener">10.1517/17425255.2012.677433</a>
3-D-QSAR and docking studies on the neuronal choline transporter.
Binding Sites; Blood-Brain Barrier/metabolism; Computer Simulation; Membrane Transport Proteins/*chemistry/metabolism; Models; Molecular; Neurons/*metabolism; Quantitative Structure-Activity Relationship; Quaternary Ammonium Compounds/chemistry
The high affinity neuronal choline transporter (CHT1) is responsible for the uptake of choline into the pre-synaptic terminal of cholinergic neurons. Considering our past experience with modeling the blood-brain barrier choline transporter (BBBCHT) as drug delivery vector to the CNS, we investigated the
Geldenhuys Werner J; Allen David D; Lockman Paul R
Bioorganic & medicinal chemistry letters
2010
2010-08
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1016/j.bmcl.2010.06.090" target="_blank" rel="noreferrer noopener">10.1016/j.bmcl.2010.06.090</a>